Bpifrance and Omnes, a European investor in private equity and infrastructure, led a $14m Series A round in AlgoTherapeutix, a France-based biotechnology company. “I am thrilled that such high-profile partners as Bpifrance and Omnes decided to support ATX01’s development journey towards a genuine relief for countless patients around the world,” Stephane Thiroloix, AlgoTherapeutix Founder & CEO.